Immunovant (IMVT) Long-Term Deferred Tax (2019)
Immunovant's (IMVT) quarterly Long-Term Deferred Tax came in at $246000.0 in Q1 2020, down 79.41% YoY from $1.2 million in Q2 2019, and up 153.61% on a QoQ basis from $97000.0 in Q3 2019.
Powered by 
Analysis
Immunovant (IMVT) Long-Term Deferred Tax (2019) Analysis & Trends
Immunovant (IMVT) has 2 years of Long-Term Deferred Tax data on file, last reported at $246000.0 in Q1 2020.
- Quarterly Long-Term Deferred Tax fell 79.41% year-over-year to $246000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $246000.0 (down 79.41% YoY) and the FY2020 annual result came in at $246000.0, down 79.41% from the prior year.
- Long-Term Deferred Tax grew to $246000.0 in Q1 2020, from $97000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.2 million in Q1 2019 to a low of $97000.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Immunovant | 8.04 Bn | 8.04 Bn | - |